Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given an average rating of “Moderate Buy” by the fifteen ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $17.40.

ATEC has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Alphatec in a research report on Monday, August 3rd. Stifel Nicolaus reduced their price target on shares of Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, July 8th. Wall Street Zen lowered shares of Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group lifted their price objective on shares of Alphatec from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, TD Cowen boosted their target price on shares of Alphatec from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th.

Insider Buying and Selling at Alphatec

In other Alphatec news, CEO Patrick Miles acquired 115,000 shares of Alphatec stock in a transaction that occurred on Thursday, September 10th. The stock was purchased at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the purchase, the chief executive officer owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. The trade was a 1.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Tyson Marshall sold 8,168 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total value of $78,821.20. Following the sale, the general counsel owned 630,398 shares of the company’s stock, valued at $6,083,340.70. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 13.48% of the company’s stock.

Institutional Trading of Alphatec

Hedge funds have recently made changes to their positions in the stock. Summit Securities Group LLC purchased a new position in Alphatec during the first quarter valued at approximately $29,000. Integrated Wealth Concepts LLC purchased a new stake in Alphatec in the 2nd quarter worth approximately $52,000. Allworth Financial LP lifted its position in Alphatec by 82.6% in the 2nd quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company’s stock worth $58,000 after buying an additional 3,015 shares in the last quarter. Lido Advisors LLC acquired a new stake in shares of Alphatec during the 1st quarter valued at $115,000. Finally, Atlas Brown Inc. acquired a new stake in shares of Alphatec during the 2nd quarter valued at $111,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $10.18 on Tuesday. The company has a market capitalization of $1.57 billion, a PE ratio of -14.34 and a beta of 0.85. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.07 and a current ratio of 1.89. The stock has a fifty day moving average of $9.41 and a 200-day moving average of $9.70. Alphatec has a one year low of $6.82 and a one year high of $23.29.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 13.49%.The firm had revenue of $213.51 million for the quarter, compared to the consensus estimate of $211.26 million. During the same quarter in the previous year, the company earned $0.02 EPS. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. As a group, equities analysts anticipate that Alphatec will post -0.45 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on improving the surgical treatment of spinal disorders. The company develops and commercializes products designed to support spine surgery, including implants, biologics, surgical instruments and related technologies.

Its portfolio is intended for procedures addressing conditions such as spinal deformities, degenerative disc disease and other disorders affecting the spine. Alphatec emphasizes surgeon-focused solutions and integrated technologies that support preoperative planning, intraoperative decision-making and the placement of spinal implants.

Headquartered in Carlsbad, California, Alphatec serves hospitals, surgeons and other healthcare providers in the United States and select international markets.